SANDERS MACHELLE 4

What Happened

• Machelle Sanders, a non-employee director of BioCryst Pharmaceuticals, received two automatic compensation grants on 2026-06-11: 15,294 restricted stock units (RSUs) and a grant of 33,540 stock options. Both items are reported as acquisitions with a reported price/value of $0.00 (standard for awards/grants in Form 4 reporting).

Key Details

• Transaction date: 2026-06-11; Filing date (Form 4): 2026-06-15 (see note on timeliness below).
• Grants reported: 15,294 RSUs (award) and 33,540 stock option grant (derivative award). Reported acquisition price/value = $0.00 for each grant.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — RSUs are an automatic non-employee director grant under the Director Compensation Policy and will vest on the first anniversary of the grant. F2 — The 33,540-unit entry represents an automatic non-employee director grant of stock options under the Director Compensation Policy.
• Timeliness: The Form 4 was filed four days after the transaction date (filed 2026-06-15 for 2026-06-11). This appears to be later than the typical two-business-day reporting requirement.

Context

• These entries are compensation grants to a non-employee director (routine director pay), not open-market purchases or sales. They do not represent an exercise or sale of options; the option grant is a derivative award, and the RSUs vest in one year per the footnote. Such awards are standard for director compensation and should be interpreted as routine grants rather than direct insider buying or selling.